How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lutetium-177 vipivotide tetraxetan

Marketing authorisation indication

2.1 Lutetium‑177 vipivotide tetraxetan (Pluvicto, Advanced Accelerator Applications) is indicated for 'the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for lutetium\u2011\177 vipivotide tetraxetan.

Price

2.3 The list price of lutetium‑177 vipivotide tetraxetan is £20,000 per 7,400 MBq single dose vial per treatment cycle (excluding VAT; company submission). The company has a commercial arrangement, which would have applied if the technology had been recommended.